This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
fcrn
FcRn
FcRn (neonatal Fc receptor; FCGRT gene; chr19q13.32) recycles IgG and albumin by pH-dependent binding in endosomes → pH 6 binding rescues from lysosomal degradation → IgG t½ ~21 days. FcRn inhibitors (efgartigimod, rozanolixizumab) reduce pathogenic IgG in autoimmune diseases.
Entry Metadata
| Field | Value |
|---|---|
| ID | fcrn |
| Name | FcRn |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725. · PubMed 17703228
- Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526-536. · PubMed 34146511
- Ward ES, Devanaboyina SC, Ober RJ. Targeting FcRn for the treatment of autoimmune diseases and alloantibody-mediated conditions. Trends Biotechnol. 2015;33(11):657-664. · PubMed 26476627